Association of early therapeutic drug monitoring of adalimumab with biologic remission and drug survival in Crohn’s Disease
ADA trough levels at week 6 are associated with BR at weeks 24 and 52, drug survival, and need for dose escalation in CD. However, ADA concentrations at week 2 failed to yield similar results.
Authors
- Joaquín Poza Cordón (ORCID: https://orcid.org/0000-0002-0501-0107)
- Jesús Noci
- Clara Amiama Roig (ORCID: https://orcid.org/0000-0002-6327-010X)
- C. Rojas (ORCID: https://orcid.org/0009-0009-0518-2329)
- María Sánchez Azofra (ORCID: https://orcid.org/0000-0002-7498-2188)
- Cristina Suárez Ferrer (ORCID: https://orcid.org/0000-0003-1789-3784)
- Laura García Ramírez (ORCID: https://orcid.org/0000-0002-5173-3381)
- J L Rueda García (ORCID: https://orcid.org/0000-0003-4487-452X)
- Eduardo Martín-Arranz
- C Cubillo García
- María Dolores Martín-Arranz
Institutions
- Hospital Universitario La Paz (ES)
- Hospital La Paz Institute for Health Research (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1177/17562848251324226
- Citations
- 2
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 3.63